NASA document reveals new Artemis II moon mission target launch dates for March

NASA quietly updated Artemis II launch windows to March 6–9 and March 11 after a wet dress rehearsal was marred by SLS hydrogen fuel leaks and a valve problem on the Orion crew capsule; the crewed four-astronaut lunar loop mission has been pushed to March pending a successful, crewless repeat rehearsal. If the fueling and systems test cannot be completed in time, agency documentation indicates the launch could instead slip to early April, prolonging schedule risk for the program and its contractors.

Analysis

Market structure: Near-term losers are prime SLS contractors (BA, AJRD, NOC, LMT exposure to Orion/SLS) as schedule slips translate to cost-to-complete and potential contract change orders; commercial launch providers and diversified defense primes (LMT, NOC to a degree) are relatively insulated and may capture reallocated spending. Delays amplify program-level bargaining power for suppliers with cryogenic expertise (Aerojet Rocketdyne) but increase procurement scrutiny and political oversight that can compress margins or slow future awards over 6–18 months.

Risk assessment: Tail risks include a failed rehearsal or in-flight anomaly leading to a multi-year Artemis pause, congressional funding caps, or supplier insolvency for small subcontractors—each would materially hurt small-cap aerospace and increase volatility in BA/AJRD by >30% peak-to-trough. Immediate horizon (days–weeks): market reprices on rehearsal outcomes; short-term (1–3 months): launch window and schedule risk; long-term (6–24 months): budget reallocation and program cost growth.

Trade implications: Expect elevated IV on BA/AJRD options; tactical short exposure to BA (and targeted puts on AJRD) for 3-month horizons, paired with modest longs in NOC or LMT as defense/heavy-lift beneficiaries. Rotate 1–4% of portfolios from pure-play space small caps into large-cap defense (NOC, LMT) and use 3-month 7–10% OTM put spreads on BA/AJRD sized 0.5–1% notional to cap cost.

Contrarian angle: Consensus prices in indefinite delays; political support historically preserves funding — a successful wet dress rehearsal (within 2 weeks) would rapidly re-rate primes. If the market sells BA/AJRD >15% on procedural delays, that is a 6–12 month buying opportunity because cashflow from defense/backstop contracts limits real downside.

Key Decisions for Investors

• Establish a 1.5% portfolio short position in BA (Boeing) sized to risk 0.5% portfolio loss; target cover if BA rallies 15% or after a successful wet dress rehearsal outcome within 14 days.
• Deploy 2% long in NOC (Northrop Grumman) or 2% long in LMT (Lockheed Martin) as defensive/defense-program exposure; target 8–15% upside over 6–12 months and trim if >20% gain.
• Purchase 3-month put spreads on BA and AJRD sized 0.5–1.0% notional each (buy 7–10% OTM puts, sell 15% OTM puts) to speculate on schedule-driven IV spikes while capping premium paid.
• Reduce exposure to pure-play space/small-cap suppliers by 30–50% within 30 days and reallocate to large-cap defense (NOC, LMT) and cash; if delays deepen and share prices fall another 10–15%, add incremental long positions up to an additional 1–2%.
• Monitor the wet dress rehearsal outcome within 7–14 days: if rehearsal succeeds, close >50% of short BA/AJRD exposure within 48 hours; if it fails or a second test is delayed past March 31, increase put exposure by 25–50%.